Search for more clinical trials
Search Trials
BRAF V600E Mutations In Papillary Thyroid Carcinoma
Conditions
Papillary Thyroid Carcinoma
Conditions: official terms
Carcinoma - Thyroid Diseases - Thyroid Neoplasms
Conditions: Keywords
papillary thyroid carcinoma, BRAF V600E, poor prognosis, aggressive
Study Type
Interventional
Study Phase
Phase 0
Study Design
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: BRAF V600E POSITIVITY
Type: Genetic
Overall Status
Recruiting
Summary
The purpose of this study is to determine whether BRAF V600E mutation in our patients with papillary thyroid cancer has an association with poor prognosis.
Detailed Description
Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy and BRAF V600E mutation is the most common genetic alteration identified in PTC, ranging from 25 to 80%, with the average rate about 45%. Various studies demonstrated a relationship between BRAF V600E mutation and aggressive characteristics of the cancer, including the worse patient prognosis. But,there are no studies from Turkey regarding this topic. So the investigators will examine BRAF V600E mutation in our patients with PTC and try to assess the role of this mutation in prognosis and further management of the patients.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: N/A
Gender: Both
Criteria: Inclusion Criteria:

- Patients with papillary thyroid cancer

Exclusion Criteria:

- Patients who do not want to be a part of this study
Location
Yeliz Emine Ersoy
Istanbul, Turkey
Status: Recruiting
Contact: Yeliz E Ersoy, DR - +905326102713 - yelizemineersoy@yahoo.com
Start Date
July 2011
Completion Date
July 2012
Sponsors
Bezmialem Vakif University
Source
Bezmialem Vakif University
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page
https://clinicaltrials.gov/show/NCT01417442